These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 33140729)

  • 41. Anthracyclines and mitochondria.
    Mordente A; Meucci E; Silvestrini A; Martorana GE; Giardina B
    Adv Exp Med Biol; 2012; 942():385-419. PubMed ID: 22399433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
    Agunbiade TA; Zaghlol RY; Barac A
    Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
    Andrieu-Abadie N
    Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
    Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
    Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardioprotection in cancer therapy: novel insights with anthracyclines.
    Raber I; Asnani A
    Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
    Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
    Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
    Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
    Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease.
    Jiang R; Lou L; Shi W; Chen Y; Fu Z; Liu S; Sok T; Li Z; Zhang X; Yang J
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes.
    Santostasi G; Kutty RK; Krishna G
    Toxicol Appl Pharmacol; 1991 Mar; 108(1):140-9. PubMed ID: 2006501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.
    Fu P; Arcasoy MO
    Biochem Biophys Res Commun; 2007 Mar; 354(2):372-8. PubMed ID: 17250809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.